- Case report
- Open Access
- Open Peer Review
Rectal perforation following paclitaxel and carboplatin chemotherapy for advanced ovarian cancer: a case report and review of the literature
© The Author(s). 2018
- Received: 5 February 2018
- Accepted: 2 July 2018
- Published: 16 August 2018
Paclitaxel is a chemotherapy drug commonly used in the management of ovarian cancer. Colonic perforation is an extremely rare complication of paclitaxel administration with few case reports in the medical literature. We report a case of a patient with advanced ovarian cancer who had a rectal perforation following administration of paclitaxel. There has only been one other case report of rectal perforation in the medical literature following paclitaxel therapy.
A 55-year-old Caucasian woman with advanced ovarian cancer awaiting elective debulking surgery for her tumor presented to our emergency department with abdominal pain, vomiting, and diarrhea. She was admitted to hospital for neoadjuvant chemotherapy and management of her systemic symptoms. She became acutely unwell following one cycle of chemotherapy with paclitaxel. A computed tomography scan of her abdomen showed typhlitis of her descending colon and a corresponding rectal perforation. Surgical intervention was deemed inappropriate as she had a heavy burden of disease and neutropenia. She died following a period of conservative management with strong intravenously administered antibiotics.
This case highlights the importance of recognizing gastrointestinal complications following chemotherapy and the need to be aware of the possibility of bowel perforation. Prompt surgical review and intervention must be requested in patients with acute abdominal pain and persistent gastrointestinal symptoms such as diarrhea and vomiting.
- Rectal perforation
Paclitaxel (Taxol®; Bristol-Myers Squibb Company, Princeton, NJ) is a biosynthetic form of the natural product taxane, which is derived from the bark of Pacific yew trees . It is an anti-microtubule agent that induces the formation of stable, non-functional microtubules by enhancing tubulin polymerization. This disrupts the dynamic equilibrium within the microtubule system and halts mitosis, preventing cell replication, and causes apoptosis .
Number of cases of bowel perforation following treatment with carboplatin and paclitaxel in the literature
Author(s) and reference number
Title of article
Type of cancer
Number of cases reported
Samejima et al. 
Rectal perforation in a patient treated with combination chemotherapy for lung cancer
Gan To Kagaku Ryoho
de Haan and van den Berg 
Colonic perforation secondary to taxol therapy: an unusual presentation
Rose and Piver 
Intestinal perforation secondary to paclitaxel
Seewaldt et al. 
Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial
Am J Obstet Gynecol
Carter and Durfee 
A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer
A 55-year-old Caucasian woman with a 5-month history of abdominal pain and vomiting was diagnosed as having a probable high-grade ovarian malignancy with a large volume of peritoneal disease. She had a prior ultrasound of her pelvis which demonstrated a 17 cm large irregular solid vascularized mass in her right ovary. Her comorbidities included obesity (body mass index of 33), asthma, and she had previously undergone a laparoscopic cholecystectomy. There was no significant family history. She did not smoke tobacco and she drank alcohol occasionally. She was scheduled for debulking surgery; however, she presented to our emergency department with worsening abdominal pain, vomiting, and diarrhea. A physical examination showed dry mucous membranes, capillary refill < 3 seconds, and jugular venous pressure of 4 cm. Her chest was clear on auscultation with dual heart sounds. Her abdomen was distended with generalized tenderness but no guarding or signs of peritonism. Bowel sounds were present. A computed tomography (CT) scan of her abdomen and pelvis was performed which demonstrated the large right ovarian tumor, peritoneal tumor deposits, and ascites. There was extrinsic compression of her sigmoid colon due to the tumor without radiological signs of large bowel obstruction. There were no other abnormalities of her bowel. She received intravenously administered fluids for rehydration, anti-emetics for nausea, and intravenously administered morphine for abdominal pain. She remained overnight in our emergency department for treatment. She was reassessed the following morning after resolution of her symptoms and was found to be hemodynamically stable and subsequently discharged home.
She re-presented 1 week later with similar symptoms and was admitted to hospital for further management. Following multidisciplinary discussion, she was recommended for neoadjuvant chemotherapy prior to surgical debulking. An urgent core biopsy of the mass confirmed the likely diagnosis of ovarian malignancy. This biopsy indicated a high-grade serous adenocarcinoma. The histology and CT findings were consistent with an International Federation of Gynaecology and Obstetrics (FIGO) stage III ovarian cancer. She was appropriately counselled as to the benefits and risks of chemotherapy prior to commencing treatment.
Gastrointestinal complications from chemotherapy range from common side effects such as vomiting and diarrhea to rarer complications such as neutropenic enterocolitis. Vomiting and diarrhea are common side effects of paclitaxel therapy. There are few case reports of neutropenic enterocolitis and reports of bowel perforation are even rarer following paclitaxel therapy.
Seewaldt et al. were the first to describe bowel perforation as a potential complication of paclitaxel therapy . They postulated a direct toxic effect of paclitaxel causing gastrointestinal necrosis as a mechanism of action. A subsequent report by these authors reported the incidence of gastrointestinal necrosis following paclitaxel to be ~ 3% (7/238 cases) . Rose and Piver reported three cases of bowel perforation following paclitaxel and also postulated a direct drug effect . Of interest, in most of these cases, bowel perforation only occurred after the first cycle suggesting that paclitaxel may simply unmask a pre-existing condition . Bowel perforation on subsequent cycles has, however, been reported [4, 5]. Concomitant administration of dexamethasone has also been considered a risk factor for intestinal perforation in paclitaxel therapy . Tumor lysis following paclitaxel therapy also possibly contributes to the occurrence of intestinal perforation .
The case described here had descending colon colitis as well as a more distal perforation in her rectum both of which looked normal on earlier imaging prior to the administration of chemotherapy. It is unusual for the rectum to develop ischemia and subsequent pneumatosis due to its excellent blood supply from the inferior mesenteric, internal iliac, and median sacral arteries. The perforation in this case was not due to tumor lysis as there was no rectal invasion by the tumor. There were also no other postulated risk factors for intestinal perforation such as concurrent corticosteroid use.
It is likely that paclitaxel has several mechanisms of action. One mechanism of action of paclitaxel has a direct effect on gastrointestinal mucosa: it arrests cellular division and promotes cell death, which leads to perforation. This was suggested by Hruban and colleagues who showed the presence of gastrointestinal mitotic arrest in autopsy-derived gastrointestinal specimens following paclitaxel treatment . There is also a secondary effect of paclitaxel treatment that leads to febrile neutropenia and typhlitis . It is highly probable that both these effects were seen in our patient leading to neutropenic colitis in her descending colon and a simultaneous perforation of her rectum. Unfortunately, both these conditions have a high morbidity and mortality once diagnosed in the immunocompromised patient. A high index of suspicion is required early on with aggressive management in the appropriate patient to treat these complications.
Clinicians need to be aware of the risk of gastrointestinal necrosis and perforation that occurs following treatment with paclitaxel, especially on the first cycle. An analysis of these complications is important in order to identify future patients at risk of these complications. The management of gastrointestinal necrosis and perforation requires early referral to the surgical team. Surgeons need to be aware of gastrointestinal complications that occur with paclitaxel treatment and with other chemotherapy agents, including the high morbidity and mortality risks associated with these complications in what are often critically unwell patients. Treatment options need to be discussed early with the patient and in a multidisciplinary setting to ensure management is not compromised. Patients also need to have an understanding of the risks of therapy.
All authors read and approved the final manuscript.
Consent for publication
Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hezari M, Croteau R. Taxol biosynthesis: an update. Planta Med. 1997;63(4):291–5.View ArticlePubMedGoogle Scholar
- Tan TH, Stevenson B, Yip D. Docetaxel-induced nasal septal perforation. Intern Med J. 2006;36(7):471–2.View ArticlePubMedGoogle Scholar
- Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 2000;27(3 Suppl 7):3–7.PubMedGoogle Scholar
- de Haan D, van den Berg M. Colonic perforation secondary to taxol therapy: an unusual presentation. Onkologie. 2006;29(11):541–2.PubMedGoogle Scholar
- Rose PG, Piver MS. Intestinal perforation secondary to paclitaxel. Gynecol Oncol. 1995;57(2):270–2.View ArticlePubMedGoogle Scholar
- Seewaldt VL, et al. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol. 1997;67(2):137–40.View ArticlePubMedGoogle Scholar
- Carter J, Durfee J. A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Gynecol Oncol. 2007;107(3):586–9.View ArticlePubMedGoogle Scholar
- Samejima J, et al. Rectal perforation in a patient treated with combination chemotherapy for lung cancer. Gan To Kagaku Ryoho. 2009;36(2):301–4.PubMedGoogle Scholar
- Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012;23(Suppl 10):x118–27.View ArticlePubMedGoogle Scholar
- Seewaldt VL, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol. 1994;170(6):1666–70. discussion 1670–1View ArticlePubMedGoogle Scholar
- Hruban RH, et al. Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer. 1989;63(10):1944–50.View ArticlePubMedGoogle Scholar
- Gadducci A, et al. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. Anticancer Res. 2005;25(3c):2509–13.PubMedGoogle Scholar